Acarix AB (ACARIX) AI Stock Analysis

• Market Cap: €257.96M
• Dividend Yield: N/A
• Average Volume (3M): 1.25M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.93
• Revenue Growth: -0.61%
• EPS Growth: 54.19%
• Country: SE
• Employees: 8
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 1,063,743,800
• 10 Day Avg. Volume: 795,097
• 30 Day Avg. Volume: 1,248,029
• PEG Ratio: 0.15
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: ―

Acarix AB's stock score reflects significant profitability challenges despite strong revenue growth and a robust balance sheet with no debt. Technical indicators suggest a bearish trend, and valuation metrics highlight the unprofitability of the company. The absence of dividend yield further detracts from its attractiveness. Overall, the company needs to improve its operational efficiency and profitability to enhance its stock potential.

Acarix AB Business Overview & Revenue Model

Company Description

Acarix AB (ACARIX) is a medical technology company specializing in diagnostic solutions for coronary artery disease. The company is focused on non-invasive, innovative products that aid in the early detection and management of heart disease. Acarix is particularly known for its CADScor System, which provides a quick and reliable way to rule out significant coronary artery disease in patients with chest pain symptoms.

How the Company Makes Money

Acarix AB generates revenue primarily through the sale of its CADScor System devices and related services. The company sells these diagnostic devices to healthcare providers, clinics, and hospitals, which use them to assess patients for coronary artery disease. Acarix may also generate income through service agreements or maintenance contracts linked to the ongoing use of its technology. Partnerships with healthcare institutions and collaborations with research entities can also play a role in expanding its market reach and enhancing its revenue streams.

Acarix AB Financial Statement Overview

Summary

Acarix AB demonstrates a solid revenue growth trajectory and maintains financial stability with a strong equity base and no debt. However, significant profitability challenges persist, with consistent operating losses impacting cash flow. While the company benefits from a healthy Gross Profit Margin, it needs to address its operational inefficiencies to enhance overall financial performance.

Income Statement

Acarix AB has shown consistent revenue growth over the years, with a notable increase from 2020 to 2021. However, the company struggles with negative EBIT and Net Income margins, indicating ongoing operational challenges and profitability issues. Despite a high Gross Profit Margin, the persistent net losses are concerning.

Balance Sheet

The company maintains a strong equity position with zero debt, reflected in a favorable Debt-to-Equity ratio. The Equity Ratio is robust, indicating financial stability. However, the company has been unable to leverage its assets effectively to generate profits, as seen in negative ROE.

Cash Flow

Operating cash flow remains negative, pointing to ongoing operational challenges. The company has managed to improve its cash position primarily through financing activities. The Free Cash Flow to Net Income Ratio indicates that operational cash flow is not supporting profitability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
6.20M	6.24M	5.82M	3.76M	2.17M
	Gross Profit
5.59M	5.30M	4.62M	2.82M	1.59M
	EBIT
-66.37M	-77.55M	-76.47M	-51.70M	-41.43M
	EBITDA
-62.63M	-77.12M	-76.12M	-50.52M	-40.29M
	Net Income Common Stockholders
-66.19M	-77.84M	-77.50M	-51.80M	-41.55M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
53.99M	35.15M	6.62M	15.81M	64.06M
	Total Assets
80.76M	62.88M	69.48M	118.60M	89.95M
	Total Debt
0.00	0.00	251.00K	523.00K	1.37M
	Net Debt
-53.99M	-35.15M	-6.37M	-15.29M	-62.70M
	Total Liabilities
5.06M	11.00M	17.66M	18.06M	7.81M
	Stockholders Equity
75.70M	51.88M	51.83M	100.54M	82.14M
Cash Flow		Free Cash Flow
-64.25M	-81.37M	-75.02M	-48.05M	-36.69M
	Operating Cash Flow
-63.33M	-81.37M	-74.87M	-48.01M	-36.69M
	Investing Cash Flow
-920.00K	0.00	-151.00K	-43.00K	0.00
	Financing Cash Flow
86.98M	106.23M	69.03M	-164.00K	47.35M

Acarix AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACARIX, the sentiment is Neutral. The current price of 0.24 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.23, and below the 200-day MA of 0.27, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.15 is Neutral, neither overbought nor oversold. The STOCH value of 31.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACARIX.

Acarix AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
INTEG.B	53 Neutral	kr466.16M	―	-19.17%	―	-12.50%	-783.92%
BRAIN	50 Neutral	€401.88M	―	-33.54%	―	72.05%	33.68%
ACARIX	46 Neutral	€257.96M	―	-88.97%	―	-0.61%	54.19%
QLINEA	43 Neutral	kr289.34M	―	-159.24%	―	-22.50%	76.74%
SCIB	43 Neutral	kr129.23M	―	-209.61%	―	27.78%	43.32%
SPEC	41 Neutral	€217.18M	―	-20.45%	―	―	-10.85%